Expressionn Of Ercc1 And Its Influence On Efficacy Of Induction Chemotherapy In Non-Small Cell Lung Cancer (Nsclc)

canquan zhou,chang su,s zhou,qiang xu,xin chen

DOI: https://doi.org/10.1200/jco.2007.25.18_suppl.18102

IF: 45.3

2007-01-01

Journal of Clinical Oncology

Abstract:18102 Background: Chemotherapy efficacy is related to pharmacogenomic differences among NSCLC patients. It is thought that up-regulated ERCC1 may be responsible for platinum resistance in NSCLC.This study was to investigate expression of ERCC1 in Chinese NSCLC patients and determine its influence on efficacy of induction chemotherapy. Methods: We retrospectively compared expression of ERCC1 between NSCLC patients receiving and not receiving induction chemotherapy. Expression of ERCC1 was detected with immunohistochemistry and defined as positive if more than 10% of tumor cells expressed ERCC1 in their nuclei. Results: Consecutive 73 NSCLC patients resected from December 1997 to Feb.1998 in our hospital were randomly selected for the study. Among them, 33 patients were given 1 to 2 cycles of cisplatin-based induction chemotherapy (mainly MVP as regimen) and their characteristics were not different from those receiving no chemotherapy. Expression of ERCC1 was higher in those younger than 60 years old than older than 60 years, in those with adenocarcinoma than in those with squamous carcinoma and in those receiving induction chemotherapy than those not receiving chemotherapy. Response (and progression) rates of induction chemotherapy were 59% (6%) and 31% (19%) in those without and with ERCC1 expression, respectively. Median survival, 3 year survival, and 5 year survival were 54 months, 53% and 35% in the patients with negative ERCC1 and 36 months, 50% and 25% in those with positive ERCC1, respectively. Difference in response rate of induction chemotherapy tended to be significant between those with and with expression of ERCC1( P<0.1). Conclusions: ERCC1 is expressed in Chinese NSCLC patients. Its expression might be induced by chemotherapy. ERCC1 in NSCLC might be useful to select patients for induction chemotherapy, which needs further study. No significant financial relationships to disclose.